Bayer acquired Vividion Therapeutics, which has developed a novel platform for identifying unrecognized binding sites on undruggable proteins, for $1.5 billion. The company has pinpointed 800 binding sites on 12,500 proteins and is developing NRF2, WRN, and STAT3 inhibitors.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.